Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee

During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.

Rheumatology

Eli Lilly & Co. is seeking US FDA approval for baricitinib to treat adults with moderate to severe rheumatoid arthritis (RA) who have inadequately responded to or cannot tolerate methotrexate, but members of the agency's Arthritis Advisory Committee suggested on April 23 that the JAK1/2 inhibitor's risk-benefit profile could limit the drug's market.

Multiple advisory committee panelists recommended baricitinib’s indication be limited to moderate to severe RA patients who have failed or can’t...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category